Fluocinolone acetonide 0.19 mg intravitreal implant improves foveal thickness and reduces treatment burden for up to 1 year in eyes with persistent diabetic macular edema

References

• Solomon SD, Chew E, Duh EJ, et al. Diabetic retinopathy: a position statement by the American Diabetes Association. Diabetes Care. 2017;40(3):412–418.28223445
   PubMed Web of Science ®Google Scholar
• International Council of Ophthalmology. ICO Guidelines for Diabetic Eye Care. San Francisco, CA: ICO; 2017.
   Google Scholar
• Klein R, Klein BEK, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XV: the long-term incidence of macular edema. Ophthalmology. 1994;102(1):7–16. doi:10.1016/S0161-6420(95)31052-4
   Web of Science ®Google Scholar
• Mathew C, Yunirakasiwi A, Sanjay S. Updates in the management of diabetic macular edema. J Diabetes Res. 2015;2015:8. doi:10.1155/2015/815839
   Web of Science ®Google Scholar
• Goncalves RS, Teixeira C, Coelho P. Recurrent diabetic macular edema: what to do. Case Rep Ophthalmol. 2017;8(3):465–474. doi:10.1159/00048011929118706
   PubMed Web of Science ®Google Scholar
• Dugel PU, Parrish R. Iluvien – a new approach to the treatment of diabetic macular edema. US Ophthalmic Rev. 2015;8:110–115. doi:10.17925/USOR.2015.08.02.110
   Google Scholar
• Zheng Y, He M, Congdon N. The worldwide epidemic of diabetic retinopathy. Indian J Ophthalmol. 2012;60(5):428–431. doi:10.4103/0301-4738.10054222944754
   PubMed Web of Science ®Google Scholar
• Lee DJ, Gomez-Marin O, Lam BL, Zheng DD. Visual acuity impairment and mortality in US adults. Arch Ophthalmol. 2002;120(11):1544–1550.12427070
   PubMedGoogle Scholar
• Kramer CK, Rodrigues TC, Canani LH, Gross JL, Azevedo MJ. Diabetic retinopathy predicts all-cause mortality and cardiovascular events in both type 1 and 2 diabetes: meta-analysis of observational studies. Diabetes Care. 2011;34(5):1238–1244. doi:10.2337/dc11-007921525504
   PubMed Web of Science ®Google Scholar
• van Hecke MV, Dekker JM, Stehouwer CDA, et al. Diabetic retinopathy is associated with mortality and cardiovascular disease incidence. EURODIAB Prospective Complications Study. 2005;28(6):1383–1389.
   Google Scholar
• Zhu X-R, Zhang Y-P, Bai L, Zhang X-L, Zhou J-B, Yang J-K. Prediction of risk of diabetic retinopathy for all-cause mortality, stroke and heart failure: evidence from epidemiological observational studies. Medicine. 2017;96(3):e5894. doi:10.1097/MD.000000000000589428099347
   PubMed Web of Science ®Google Scholar
• Siantar RG, Cheng C-Y, Gemmy Cheung CM, et al. Impact of visual impairment and eye diseases on mortality: the Singapore Malay Eye Study (SiMES). Sci Rep. 2015;5:16304. doi:10.1038/srep1630426549406
   PubMed Web of Science ®Google Scholar
• Nathan DM, Genuth S, Lachin J, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–986. doi:10.1056/NEJM1993093032914018366922
   PubMed Web of Science ®Google Scholar
• Stratton IM, Kohner EM, Aldington SJ, et al. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia. 2001;44(2):156–163. doi:10.1007/s00125005159411270671
   PubMed Web of Science ®Google Scholar
• Bressler SB, Qin H, Melia M, et al. Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. JAMA Ophthalmol. 2013;131(8):1033–1040. doi:10.1001/jamaophthalmol.2013.415423807371
   PubMed Web of Science ®Google Scholar
• Haddrill M 2017 http://www.allaboutvision.com/conditions/diabetic-treatment.htm. Accessed 43, 2017.
   Google Scholar
• Saedon H, Anand A, Yang YC. Clinical utility of intravitreal fluocinolone acetonide (Iluvien) implant in the management of patients with chronic diabetic macular edema: a review of the current literature. Clin Ophthalmol. 2017;11:583–590. doi:10.2147/OPTH.S13116528392675
   PubMed Web of Science ®Google Scholar
• Alimera Sciences. Iluvien (fluocinolone acetonide intravitreal implant) 0.19 mg for intravitreal injection. Alpharetta, GA: Alimera Sciences, Inc; 2016.
   Google Scholar
• Campochiaro PA, Brown DM, Pearson A, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011;118(4):626–635.e622. doi:10.1016/j.ophtha.2010.12.02821459216
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119(10):2125–2132. doi:10.1016/j.ophtha.2012.04.03022727177
   PubMed Web of Science ®Google Scholar
• Elaraoud I, Attawan A, Quhill F. Case series investigating the efficacy and safety of bilateral fluocinolone acetonide (Iluvien) in patients with diabetic macular edema. Ophthalmol Ther. 2016;5(1):95–104. doi:10.1007/s40123-016-0045-726885863
   PubMed Web of Science ®Google Scholar
• Meireles A, Goldsmith C, El-Ghrably I, et al. Efficacy of 0.2 mug/day fluocinolone acetonide implant (Iluvien) in eyes with diabetic macular edema and prior vitrectomy. Eye (Lond). 2017;31(5):684–690. doi:10.1038/eye.2016.30328085139
   PubMed Web of Science ®Google Scholar
• Currie CJ, Holden SE, Berni E, Owens DR. Evaluation of the clinical effectiveness of fluocinolone acetonide 190 microg intravitreal implant in diabetic macular edema: a comparison between study and fellow eyes. Curr Med Res Opin. 2017;33(sup2):19–31. doi:10.1080/03007995.2017.136665928881143
   PubMed Web of Science ®Google Scholar
• Currie CJ, Holden SE, Owens DR. Patterns of retinal thickness prior to and following treatment with fluocinolone acetonide 190 microg intravitreal implant for diabetic macular edema. Curr Med Res Opin. 2017;33(sup2):33–43. doi:10.1080/03007995.2017.136666228881150
   PubMed Web of Science ®Google Scholar
• Holden SE, Currie CJ, Owens DR. Evaluation of the clinical effectiveness in routine practice of fluocinolone acetonide 190 microg intravitreal implant in people with diabetic macular edema. Curr Med Res Opin. 2017;33(sup2):5–17. doi:10.1080/03007995.2017.1366645
   PubMed Web of Science ®Google Scholar
• Schmit-Eilenberger VK. A novel intravitreal fluocinolone acetonide implant (Iluvien) in the treatment of patients with chronic diabetic macular edema that is insufficiently responsive to other medical treatment options: a case series. Clin Ophthalmol. 2015;9:801–811. doi:10.2147/OPTH.S7978525999689
   PubMed Web of Science ®Google Scholar
• Eaton A, Koh SS, Jimenez J, Riemann CD. The USER study: a chart review of patients receiving a 0.2 µg/day fluocinolone acetonide implant for diabetic macular edema. Opthalmology Ther. 2019;8(1):51–62. doi:10.1007/s40123-018-0155-5
   PubMed Web of Science ®Google Scholar